Funding for preventive AIDS vaccine research increased by four percent to US$881 million—the highest investment seen since 2007. The public sector accounted for 80 percent of overall funding at US$714 million, with the US public sector leading contributions at US$667 million or 93 percent of all public funding. This marked the highest US investment in the past 16 years and helped offset decreases from the European public sector (down 12 percent to US$38.5 million) and the philanthropic sector (down eight percent to US$126 million). Commercial funding also decreased by 13 percent and amounted to US$54 million.
In 2016, investments for AIDS vaccines were allocated mostly to preclinical research (44.7 percent), followed by clinical trials (36 percent) and basic research (16.7 percent). These allocations reflect a shifting emphasis to preclinical research and could be explained by the cyclical nature of trials and the preponderance of studies in preclinical stages.